CoChat

Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter

Open access
Sun, Baodong, Zhang, Haoyue, Franco, Luis M., Brown, Talmage, Bird, Andrew, Schneider, Ayn, Koeberl, Dwight D. · 2005 · Molecular Therapy
Cited by 111

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Glycogen storage disease type II (Pompe disease) causes death in infancy from cardiorespiratory failure due to acid alpha-glucosidase (GAA; acid maltase) deficiency. An AAV2 vector pseudotyped as AAV6 (AAV2/6 vector) transiently expressed high-level human GAA in GAA-knockout (GAA-KO) mice without reducing glycogen storage; however, in immunodeficient GAA-KO/SCID mice the AAV2/6 vector expressed high-level GAA and reduced the glycogen content of the injected muscle for 24 weeks. A CD4+/CD8+ lymphocytic infiltrate was observed in response to the AAV2/6 vector in immunocompetent GAA-KO mice. When a muscle-specific creatine kinase promoter was substituted for the CB promoter (AAV-MCKhGAApA), that AAV2/6 vector expressed high-level GAA and reduced glycogen content in immunocompetent GAA-KO mice. Muscle-restricted expression of hGAA provoked only a humoral (not cellular) immune response. Intravenous administration of a high number of particles of AAV-MCKhGAApA as AAV2/7 reduced the glycogen content of the heart and skeletal muscle and corrected individual myofibers in immunocompetent GAA-KO mice 24 weeks postinjection. In summary, persistent correction of muscle glycogen content was achieved with an AAV vector containing a muscle-specific promoter in GAA-KO mice, and this approach should be considered for muscle-targeted gene therapy in Pompe disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2005.01.012

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 39

  1. Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc. Natl. Acad. Sci. USA, 96, 8861, 10.1073/pnas.96.16.8861 · DOI · Paper page
  2. Pauly, 2001, Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease, Hum. Gene Ther., 12, 527, 10.1089/104303401300042447 · DOI
  3. Ding, 2001, Long-term efficacy after [E1−, polymerase−] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice, Hum. Gene Ther., 12, 955, 10.1089/104303401750195917 · DOI · Paper page
  4. Raben, 2003, Enzyme replacement therapy in the mouse model of Pompe disease, Mol. Genet. Metab., 80, 159, 10.1016/j.ymgme.2003.08.022 · DOI · Paper page
  5. Pauly, 1998, Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle, Gene Ther., 5, 473, 10.1038/sj.gt.3300609 · doi:10.1038/sj.gt.3300609
  6. Fraites, 2002, Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors, Mol. Ther., 5, 571, 10.1006/mthe.2002.0580 · DOI · Paper page
  7. Sun, 2003, Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector, Mol. Ther., 7, 467, 10.1016/S1525-0016(03)00022-4 · DOI
  8. Sun, 2003, Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector, Mol. Ther., 7, 193, 10.1016/S1525-0016(02)00055-2 · DOI
  9. Rabinowitz, 2002, Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol., 76, 791, 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
  10. Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
  11. Rutledge, 1998, Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 1, J. Virol., 72, 309, 10.1128/JVI.72.1.309-319.1998 · DOI · Paper page
  12. Ferrer, 2000, Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy, Gene Ther., 7, 1439, 10.1038/sj.gt.3301259 · DOI
  13. Hauser, 2000, Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors, Mol. Ther., 2, 16, 10.1006/mthe.2000.0089 · DOI · Paper page
  14. Shield, 1996, E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice, Mol. Cell. Biol., 16, 5058, 10.1128/MCB.16.9.5058 · DOI · Paper page
  15. Yuasa, 2002, Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product, Gene Ther., 9, 1576, 10.1038/sj.gt.3301829 · DOI
  16. Ding, 2002, Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction, Mol. Ther., 5, 436, 10.1006/mthe.2002.0563 · DOI
  17. Raben, 2001, Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy, Hum. Mol. Genet., 10, 2039, 10.1093/hmg/10.19.2039 · DOI
  18. Fraites, 2002, Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors, Mol. Ther., 5, 571, 10.1006/mthe.2002.0580 · DOI · Paper page
  19. Wang, 1999, Sustained correction of bleeding disorder in hemophilia B mice by gene therapy, Proc. Natl. Acad. Sci. USA, 96, 3906, 10.1073/pnas.96.7.3906 · DOI · Paper page
  20. Monahan, 1998, Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia, Gene Ther., 5, 40, 10.1038/sj.gt.3300548 · DOI · Paper page
  21. Herzog, 2002, Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy, Hum. Gene Ther., 13, 1281, 10.1089/104303402760128513 · DOI · Paper page
  22. Zolotukhin, 2002, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther., 6, 973, 10.1038/sj.gt.3300938 · DOI · Paper page
  23. Halbert, 2001, Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors, J. Virol., 75, 6615, 10.1128/JVI.75.14.6615-6624.2001 · DOI · Paper page
  24. O’Riordan, 2000, Scalable chromatographic purification process for recombinant adeno-associated virus (rAAV), J. Gene Med., 2, 444, 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1 · DOI
  25. Kaludov, 2002, Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography, Hum. Gene Ther., 13, 1235, 10.1089/104303402320139014 · DOI · Paper page
  26. Gao, 2000, Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo, Hum. Gene Ther., 11, 2079, 10.1089/104303400750001390 · DOI · Paper page
  27. Liu, 2003, Optimized production of high-titer recombinant adeno-associated virus in roller bottles, Biotechniques, 34, 184, 10.2144/03341dd07 · DOI · Paper page
  28. Zhang, 1999, High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H, Hum. Gene Ther., 10, 2527, 10.1089/10430349950016861 · DOI · Paper page
  29. Urabe, 2002, Insect cells as a factory to produce adeno-associated virus type 2 vectors, Hum. Gene Ther., 13, 1935, 10.1089/10430340260355347 · DOI · Paper page
  30. Amalfitano, 1997, Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy, Gene Ther., 4, 258, 10.1038/sj.gt.3300378 · DOI
  31. He, 1998, A simplified system for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. USA, 95, 2509, 10.1073/pnas.95.5.2509 · DOI · Paper page
  32. Fang, 2003, Development of a new, immune-deficient, GSD-II mouse model confirms that anti-GAA antibody can limit the efficacy of gene therapy for GSD-II, Mol. Ther., 7, S390, 10.1016/S1525-0016(16)41454-1 · doi:10.1016/s1525-0016(16)41454-1
  33. Raben, 1998, Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II, J. Biol. Chem., 273, 19086, 10.1074/jbc.273.30.19086 · DOI · Paper page
  34. Fujimori, 1997, The murine DNA-PKcs gene consists of 86 exons dispersed in more then 250 kb, Genomics, 45, 194, 10.1006/geno.1997.4919 · DOI
  35. Blunt, 1996, Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse, Proc. Natl. Acad. Sci. USA, 93, 10285, 10.1073/pnas.93.19.10285 · DOI · Paper page
  36. Araki, 1997, Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice, Proc. Natl. Acad. Sci. USA, 94, 2438, 10.1073/pnas.94.6.2438 · DOI · Paper page
  37. Kikuchi, 1998, Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail, J. Clin. Invest., 101, 827, 10.1172/JCI1722 · DOI · Paper page
  38. Van Hove, 1996, High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proc. Natl. Acad. Sci. USA, 93, 65, 10.1073/pnas.93.1.65 · DOI
  39. Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc. Natl. Acad. Sci. USA, 96, 8861, 10.1073/pnas.96.16.8861 · DOI · Paper page

Cited by

See all 111

Metadata

Authors
Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2005-06
Volume
11
Issue
6
Pages
889-898
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2034661134
Cited by
111
References
8
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. https://app.cochat.ai/papers/10.1016/j.ymthe.2005.01.012
The paper
Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D. (2005). Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2005.01.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.